BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript

For the period ending December 31, 2024

February 24, 2025 8:30 a.m. ET

Prepared Remarks

Questions and Answers

Call Participants

Prepared Remarks:

Operator

Good morning, and welcome to the BioCryst Fourth Quarter 2024 Earnings Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to John Bluth at BioCryst. Please go ahead.

John Bluth

Thanks, Drew. Good morning, and welcome to BioCryst's fourth quarter 2024 corporate update and financial results conference call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Commercial Officer, Charlie Gayer; and Chief R&D Officer, Dr. Helen Thackray. Following our remarks, we'll answer your questions.

Today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation.

You should not place undue reliance on these forward-looking statements. For additional information, including a detailed discussion of our risk factors, please refer to the company documents filed with the Securities and Exchange Commission, which can be accessed on our website.

In addition, today's conference call includes non-GAAP financial measures. For a reconciliation of these non-GAAP measures against the most directly comparable GAAP financial measure, please refer to the earnings release posted in the Press Releases section of our Investor Relations website at www.biocryst.com.

Now, I'd like to turn the call over to Jon Stonehouse.

Jon Stonehouse

Thank you, John. We ended 2024 with the strongest execution and performance in the company's history. What's even more exciting is, it happened across the company. For the full year 2024, ORLADEYO revenue year-over-year grew by 34% and we added as many patients as we did in the first year of launch. This is an amazing result for a rare disease medicine, especially, considering it came in the fourth year on the market and reflects excellent execution by the commercial team.

Next on the clinical front, we now have the data from our pediatric clinical trial with ORLADEYO to put us in a position to file the NDA this year. We also advanced BCX17725 for Netherton syndrome into the clinic and made progress with the avoralstat for DME that will enable us to put that program into the clinic this year.